BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bull-Otterson L, Huang YA, Zhu W, King H, Edlin BR, Hoover KW. Human Immunodeficiency Virus and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017. J Infect Dis 2020;222:940-7. [PMID: 32002537 DOI: 10.1093/infdis/jiaa017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Stevenson N, Suttie S, Fernandes E, Rae N. Acute infections in people who inject drugs. BMJ 2022;379:e072635. [PMID: 36207027 DOI: 10.1136/bmj-2022-072635] [Reference Citation Analysis]
2 Jiang X, Diaby V, Vouri SM, Lo-ciganic W, Parker RL, Wang W, Chang S, Wilson DL, Henry L, Park H. Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs. American Journal of Preventive Medicine 2022. [DOI: 10.1016/j.amepre.2022.08.016] [Reference Citation Analysis]
3 Yuan JM, Croxford S, Viviani L, Emanuel E, Phipps E, Desai M. Investigating the sociodemographic and behavioural factors associated with hepatitis C virus testing amongst people who inject drugs in England, Wales and Northern Ireland: A quantitative cross-sectional analysis. Int J Drug Policy 2022;109:103821. [PMID: 35994940 DOI: 10.1016/j.drugpo.2022.103821] [Reference Citation Analysis]
4 Peiper NC, Shamblen S, Gilbertson A, Guest G, Kopp M, Guy L, Rose MR. Acceptability of a HIV self-testing program among people who use illicit drugs. International Journal of Drug Policy 2022;103:103613. [DOI: 10.1016/j.drugpo.2022.103613] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jawa R, Stein MD, Anderson B, Liebschutz JM, Stewart C, Phillips KT, Barocas JA. Behavioral Risk Factors for HIV Infection in Hospitalized Persons Who Co-use Stimulants and Opioids. AIDS Behav 2022;26:1047-55. [PMID: 34510289 DOI: 10.1007/s10461-021-03460-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Parish WJ, Mark TL, Zarkin GA, Weber E. The association of Medicare Part D prior authorization for buprenorphine-naloxone with adherence to opioid use disorder treatment guidelines in the United States. Addiction 2022;117:141-50. [PMID: 34033177 DOI: 10.1111/add.15585] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Perkins M, Slevin A, Strand MA, Freisner D. Screening at a Federally Qualified Health Center in the Midwest for Hepatitis C Among People Who Inject Drugs, 2019-2020. Prev Chronic Dis 2021;18:E69. [PMID: 34264813 DOI: 10.5888/pcd18.200604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jiang X, Parker RL, Vouri SM, Lo-Ciganic W, Diaby V, Henry L, Park H. Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders. Am J Prev Med 2021:S0749-3797(21)00271-3. [PMID: 34210584 DOI: 10.1016/j.amepre.2021.04.013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Feld JJ, Ward JW. Key Elements on the Pathway to HCV Elimination: Lessons Learned From the AASLD HCV Special Interest Group 2020. Hepatol Commun 2021;5:911-22. [PMID: 34141979 DOI: 10.1002/hep4.1731] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
10 Mirzazadeh A, Chen YH, Lin J, Burk K, Wilson EC, Miller D, Veloso D, McFarland W, Morris MD. Progress toward closing gaps in the hepatitis C virus cascade of care for people who inject drugs in San Francisco. PLoS One 2021;16:e0249585. [PMID: 33798243 DOI: 10.1371/journal.pone.0249585] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
11 Muncan B, Jordan AE, Perlman DC, Frank D, Ompad DC, Walters SM. Acceptability and Effectiveness of Hepatitis C Care at Syringe Service Programs for People Who Inject Drugs in New York City. Subst Use Misuse 2021;56:728-37. [PMID: 33682610 DOI: 10.1080/10826084.2021.1892142] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
12 Linas BP. Time for a New Approach to Guidance for Human Immunodeficiency Virus and Hepatitis C Virus Testing Among Persons Who Inject Drugs. J Infect Dis 2020;222:885-7. [PMID: 32002538 DOI: 10.1093/infdis/jiaa015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lloyd M, Ransom EM, Anderson NW, Farnsworth CW. Evaluation of Infectious Disease Test Ordering and Positivity Rates in Illicit Fentanyl Users. J Appl Lab Med 2021;6:79-92. [PMID: 33313803 DOI: 10.1093/jalm/jfaa194] [Reference Citation Analysis]
14 Farnsworth CW, Lloyd M, Jean S. Opioid Use Disorder and Associated Infectious Disease: The Role of the Laboratory in Addressing Health Disparities. J Appl Lab Med 2021;6:180-93. [PMID: 33438735 DOI: 10.1093/jalm/jfaa150] [Reference Citation Analysis]
15 Lloyd M, Farnsworth CW. The Opioid Epidemic: Associated Infections and Diagnostic Methods. Clinical Microbiology Newsletter 2020;42:145-155. [DOI: 10.1016/j.clinmicnews.2020.08.003] [Reference Citation Analysis]